Key trials presented at the sessions include:
- ADVANCE: New LVAD equivalent to HeartMate II, nonrandomized study shows
- RAFT: CRT shows survival benefit for patients with class 2 and 3 HF who have low EF and wide QRS
- EMPHASIS-HF: Eplerenone shows large benefits in milder heart failure
- ASCEND HF: Nesiritide safe but of limited dyspnea benefit in acute HF
- ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds
- CLOSURE I: No overall benefit, no reduction in stroke or TIA with PFO closure
- GRAVITAS: No benefit of doubling dose in clopidogrel nonresponders
- P-OM3: Omega-3 PUFA caps don't suppress paroxysmal AF in randomized trial
- BASKET-PROVE: DES as safe as bare-metal stents in larger coronary arteries, with less TVR
- DEFINE: Large effects on LDL and HDL cholesterol with CETP inhibitor anacetrapib
- SYMPLICITY HTN: Catheter-based renal denervation reduces BP in patients with resistant hypertension
- ASCOT CRP: Analysis fuels debate over JUPITER-based CRP indication for statins
- ACT: No benefit of N-acetylcysteine to reduce contrast-induced nephropathy
Posts
No comments:
Post a Comment
Add your comment